

Shandong Boan Biotechnology Co., Ltd.

山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代號: 6955)

29 February 2024

Dear registered H shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Shandong Boan Biotechnology Co., Ltd. (the “**Company**”) is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “**Corporate Communications**”), which mean any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.boan-bio.com/ and the HKEXnews website at www.hkexnews.hk/ in place of printed copies. The Company will send the Actionable Corporate Communications^(Note) to its registered H shareholders individually in electronic form by email.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications^(Note), the Company recommends you to provide your email address by scanning your personalized QR code printed on the reply form on the reverse side (the “**Reply Form**”). Alternatively, you may sign and return the Reply Form to the Company’s H share registrar (the “**H Share Registrar**”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the H Share Registrar, the Company will send you the Actionable Corporate Communications^(Note) in printed form in the future.

It is your responsibility to provide email address that is functional. If the Company does not possess your email address or the email address provided is not functional, the Company will act according to the above arrangements. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by you without receiving any “non-delivery message”.

If you want to receive the Corporate Communications in printed form, please complete and return the Reply Form to the H Share Registrar or send an email to boan.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the H Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Monday to Friday, excluding Hong Kong public holidays.

Yours faithfully,
By order of the Board
SHANDONG BOAN BIOTECHNOLOGY CO., LTD.
Jiang Hua
Chairlady, Chief Executive Officer and Executive Director

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.

各位登記 H 股股東：

以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下的香港聯合交易所有限公司證券上市規則（「**上市規則**」）第 2.07A 條，山東博安生物技术股份有限公司（「**公司**」）謹此通知 閣下，公司已採用以電子方式發布公司通訊（「**公司通訊**」），該公司通訊是指公司已發布或將予發布以供其任何證券持有人或投資大眾參照或採取行動的任何文件，包括但不限於(a) 董事報告、其年度帳目以及審計報告副本以及（如適用）其財務摘要報告；(b) 中期報告及（如適用）其中期報告摘要；(c) 會議通告；(d) 上市文件；(e) 通函；及 (f) 代表委任表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 www.boan-bio.com/ 和披露易網站 www.hkexnews.hk/ 上提供，以代替印刷本。公司將以電子方式（通過電子郵件）向登記 H 股股東個別地發送可供採取行動的公司通訊^(附註)。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊^(附註)，公司建議 閣下透過掃描本函背頁之回條（「**回條**」）上列印的 閣下專屬二維碼提供 閣下的電子郵件地址。或者， 閣下亦可以簽署回條並交回公司的 H 股股份過戶登記處（「**H 股股份過戶處**」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果公司沒有收到 閣下有效的電子郵件地址，公司未來將以印刷本形式向 閣下發送可供採取行動的公司通訊^(附註)，直至 H 股股份過戶處收到 閣下有效的電子郵件地址。

閣下有責任提供有效的電子郵件地址。假若公司沒有收到 閣下的電子郵件地址或 閣下所提供的電子郵件地址無法使用，公司將按照上述安排行事。如果公司發送可供採取行動的公司通訊到 閣下提供的電子郵件地址而未收到任何「未送達信息」，則公司將被視為已遵守上市規則。

若 閣下希望收取公司通訊之印刷版，請填妥回條並交回 H 股股份過戶處，或發送電子郵件至 boan.ecom@computershare.com.hk，並註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。請注意，收取未來公司通訊印刷版之指示由收悉 閣下指示日期起計一年內有效，此後將過期。

如 閣下對本函件有任何疑問，請於辦公時間星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正（香港時間）期間致電 H 股股份過戶處(852)2862 8688 查詢。

承董事會命
山东博安生物技术股份有限公司
主席、首席執行官及執行董事
姜華
謹啟

2024 年 2 月 29 日

附註：可供採取行動的公司通訊指任何涉及及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

